BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 16455634)

  • 1. Bone marrow transplantation nephropathy after an intensified conditioning regimen with radioimmunotherapy and allogeneic stem cell transplantation.
    Zenz T; Schlenk RF; Glatting G; Neumaier B; Blumstein N; Buchmann I; von Harsdorf S; Ringhoffer M; Wiesneth M; Keller F; Kotzerke J; Röttinger E; Stilgenbauer S; Döhner H; Reske SN; Bunjes D
    J Nucl Med; 2006 Feb; 47(2):278-86. PubMed ID: 16455634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 188Re or 90Y-labelled anti-CD66 antibody as part of a dose-reduced conditioning regimen for patients with acute leukaemia or myelodysplastic syndrome over the age of 55: results of a phase I-II study.
    Ringhoffer M; Blumstein N; Neumaier B; Glatting G; von Harsdorf S; Buchmann I; Wiesneth M; Kotzerke J; Zenz T; Buck AK; Schauwecker P; Stilgenbauer S; Döhner H; Reske SN; Bunjes D
    Br J Haematol; 2005 Aug; 130(4):604-13. PubMed ID: 16098076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term results of selective renal shielding in patients undergoing total body irradiation in preparation for bone marrow transplantation.
    Lawton CA; Cohen EP; Murray KJ; Derus SW; Casper JT; Drobyski WR; Horowitz MM; Moulder JE
    Bone Marrow Transplant; 1997 Dec; 20(12):1069-74. PubMed ID: 9466280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radioimmunotherapy for the intensification of conditioning before stem cell transplantation: differences in dosimetry and biokinetics of 188Re- and 99mTc-labeled anti-NCA-95 MAbs.
    Kotzerke J; Glatting G; Seitz U; Rentschler M; Neumaier B; Bunjes D; Duncker C; Dohr D; Bergmann L; Reske SN
    J Nucl Med; 2000 Mar; 41(3):531-7. PubMed ID: 10716329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 188Re anti-CD66 radioimmunotherapy combined with reduced-intensity conditioning and in-vivo T cell depletion in elderly patients undergoing allogeneic haematopoietic cell transplantation.
    Lauter A; Strumpf A; Platzbecker U; Schetelig J; Wermke M; Radke J; Kiani A; Wunderlich G; Thiede C; Ehninger G; Kotzerke J; Bornhäuser M
    Br J Haematol; 2010 Mar; 148(6):910-7. PubMed ID: 19995390
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced renal toxicity of total body irradiation combined with radioimmunotherapy.
    Röttinger EM; Bartkowiak D; Bunjes D; Wennauer R; Dohr D
    Strahlenther Onkol; 2003 Oct; 179(10):702-7. PubMed ID: 14566479
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted marrow irradiation with radioactively labeled anti-CD66 monoclonal antibody prior to allogeneic stem cell transplantation for patients with leukemia: results of a phase I-II study.
    Zenz T; Glatting G; Schlenk RF; Buchmann I; Döhner H; Reske SN; Bunjes D
    Haematologica; 2006 Feb; 91(2):285-6. PubMed ID: 16461327
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term follow-up of allogeneic hematopoietic stem cell transplantation for de novo acute myelogenous leukemia with a conditioning regimen of total body irradiation and granulocyte colony-stimulating factor-combined high-dose cytarabine.
    Mori T; Aisa Y; Watanabe R; Yamazaki R; Kato J; Shimizu T; Shigematsu N; Kubo A; Yajima T; Hibi T; Ikeda Y; Okamoto S
    Biol Blood Marrow Transplant; 2008 Jun; 14(6):651-7. PubMed ID: 18489990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myeloablative radioimmunotherapy with Re-188-anti-CD66-antibody for conditioning of high-risk leukemia patients prior to stem cell transplantation: biodistribution, biokinetics and immediate toxicities.
    Buchmann I; Bunjes D; Kotzerke J; Martin H; Glatting G; Seitz U; Rattat D; Buck A; Döhner H; Reske SN
    Cancer Biother Radiopharm; 2002 Apr; 17(2):151-63. PubMed ID: 12030109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regimen-related mucosal injury of the gut increased the incidence of CMV disease after allogeneic bone marrow transplantation.
    Shigematsu A; Yasumoto A; Yamamoto S; Sugita J; Kondo T; Onozawa M; Kahata K; Endo T; Ota S; Sato N; Takahata M; Okada K; Tanaka J; Hashino S; Nishio M; Koike T; Asaka M; Imamura M
    Biol Blood Marrow Transplant; 2009 Jun; 15(6):679-85. PubMed ID: 19450752
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytoreduction with iodine-131-anti-CD33 antibodies before bone marrow transplantation for advanced myeloid leukemias.
    Burke JM; Caron PC; Papadopoulos EB; Divgi CR; Sgouros G; Panageas KS; Finn RD; Larson SM; O'Reilly RJ; Scheinberg DA; Jurcic JG
    Bone Marrow Transplant; 2003 Sep; 32(6):549-56. PubMed ID: 12953125
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Myeloablative radioimmunotherapy with 188Re-CD66mAb before stem cell transplantation. No increase of proinflammatory cytokine levels of TNF-alpha].
    Mutschler J; Steinbach G; Bunjes D; Reske SN; Buchmann I
    Nuklearmedizin; 2009; 48(1):30-6. PubMed ID: 19212609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cataracts after autologous bone marrow transplantation in children.
    Frisk P; Hagberg H; Mandahl A; Söderberg P; Lönnerholm G
    Acta Paediatr; 2000 Jul; 89(7):814-9. PubMed ID: 10943964
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term outcome after bone marrow transplantation for aplastic anemia using cyclophosphamide and total lymphoid irradiation as conditioning regimen.
    Inamoto Y; Suzuki R; Kuwatsuka Y; Yasuda T; Takahashi T; Tsujimura A; Sugimoto K; Oba T; Terakura S; Atsuta Y; Murata M; Ito M; Kodera Y; Miyamura K
    Biol Blood Marrow Transplant; 2008 Jan; 14(1):43-9. PubMed ID: 18158960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 188Re-labeled anti-CD66 monoclonal antibody in stem cell transplantation for patients with high-risk acute myeloid leukemia.
    Bunjes D
    Leuk Lymphoma; 2002 Nov; 43(11):2125-31. PubMed ID: 12533037
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Total body irradiation and granulocyte colony-stimulating factor-combined high-dose cytarabine as a conditioning regimen in allogeneic hematopoietic stem cell transplantation for advanced myelodysplastic syndrome: a single-institute experience.
    Mori T; Aisa Y; Yokoyama A; Nakazato T; Yamazaki R; Shimizu T; Mihara A; Kato J; Watanabe R; Takayama N; Ikeda Y; Okamoto S
    Bone Marrow Transplant; 2007 Feb; 39(4):217-21. PubMed ID: 17220902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Re-186 HEDP conditioning therapy in patients with advanced acute lymphoblastic leukemia before allogeneic bone marrow transplantation.
    Döbert N; Martin H; Kranert WT; Menzel C; Klein SA; Mose S; Grünwald F
    Clin Nucl Med; 2003 Sep; 28(9):738-42. PubMed ID: 12972995
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term results of allogeneic bone marrow transplantation for 108 adult patients with acute lymphoblastic leukemia: favorable outcome with BMT at first remission and HLA-matched unrelated donor.
    Chim CS; Lie AK; Liang R; Au WY; Kwong YL
    Bone Marrow Transplant; 2007 Aug; 40(4):339-47. PubMed ID: 17572712
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bone marrow transplantation from unrelated donors for patients with adult T-cell leukaemia/lymphoma.
    Nakase K; Hara M; Kozuka T; Tanimoto K; Nawa Y
    Bone Marrow Transplant; 2006 Jan; 37(1):41-4. PubMed ID: 16247419
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Terminal deoxynucleotidyl transferase-positive cells in trephine biopsies following bone marrow or peripheral stem cell transplantation reflect vigorous B-cell generation.
    Wolf E; Harms H; Winkler J; Reulbach U; Kirchner T; Niedobitek G; Baumann I
    Histopathology; 2005 Apr; 46(4):442-50. PubMed ID: 15810956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.